Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590939 | 0.89 | AMY1A (0.35) | AMY1AMEP1BGAAHSD17B10TAAR1 | |
| SCHEMBL10592891 | 0.89 | AMY1A (0.35) | AMY1AMEP1BGAAHSD17B10TAAR1 | |
| SCHEMBL10817238 | 0.83 | GAA (0.35) | AMY1AMEP1BGAAHSD17B10TAAR1 | |
| SCHEMBL17633977 | 0.81 | TAAR1 (0.33) | AMY1AMEP1BHSD17B10TAAR1ALDH1A1 | |
| SCHEMBL6959650 | 0.81 | TDP1 (0.47) | ALDH1A1TDP1POLBKMT2A | |
| SCHEMBL7387360 | 0.81 | TDP1 (0.47) | ALDH1A1TDP1POLBKMT2A | |
| SCHEMBL10926819 | 0.79 | ALDH1A1 (0.35) | AMY1AMEP1BGAAHSD17B10TAAR1 | |
| SCHEMBL6604579 | 0.78 | TAAR1 (0.40) | AMY1AMEP1BGAAHSD17B10TAAR1 | |
| SCHEMBL6604226 | 0.78 | TDP1 (0.43) | GAAALDH1A1TDP1KMT2A | |
| SCHEMBL4240713 | 0.78 | GAA (0.37) | AMY1AMEP1BGAAHSD17B10TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | disclosed |
| CN-107106709-B | Radiopharmaceutical conjugates comprising a metabolite and an EPR agent targeting tumor cells | 南非核能源有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| EP-3197504-A2 | RADIOPHARMACEUTICAL CONJUGATE OF A METABOLITE AND AN EPR AGENT, FOR TARGETING TUMOUR CELLS | The South African Nuclear Energy Corporation Limited (ZA) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046793-A2 | RADIOPHARMACEUTICAL CONJUGATE | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | AMY1A 4705/4885MEP1B 1930/4885GAA 265/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | AMY1A 4649/4885MEP1B 2227/4885GAA 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.